The near term future in CAR-T cells is a’changing!
It’s hard to imagine It’s now almost a decade on since eagerly reading the seminal CRISPR papers from the Doudna/Charpentier and Zhang labs in Science, but what a ride it’s been!
The cool thing here is we’re now getting closer to seeing clinical grade oncology products using base editing, a next generation approach with greater precision in terms of the cuts achieved.
This technology has important implications, not only for novel CAR-T cell therapy developments (which we will be covering in more detail going forward), but also other diseases where base pair changes are necessary to address the underlying root cause of the disease.
In our latest expert interview, we caught up with the CEO of one of the ompanies active in this space for a fun science discussion about the potential implications for new product development in a variety of key topics….
To continue reading our latest highlights on oncology new product development including an expert interview, BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
